View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
June 26, 2020

Coronavirus company news summary – EMA grants conditional approval to remdesivir – Avalon GloboCare starts studies of vaccine with intranasal or oral administration

By Allie Nawrat

26 June 2020 

US-based biotech firm Avalon GloboCare has collaborated with the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria, to develop an S-layer vaccine against Covid-19 for intranasal or oral administration. The partners are working to develop a vaccine candidate that would trigger an immune response sufficient to prevent a severe form of Covid-19 infection.

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recommended the conditional marketing authorisation of Gilead Sciences’ remdesivir under the brand name Veklury for Covid-19 patients aged 12 years and above with pneumonia who require supplemental oxygen. The drug is the first Covid-19 medicine to be recommended for authorisation in the European Union (EU).

The Federal University of Sao Paulo (Unifesp), Brazil is in discussions to assess a Covid-19 vaccine candidate developed by Italian researchers at Lazzaro Spallanzani National Institute, as reported by Reuters. The Italian researchers intend to perform mid-stage and final Phase III trials in Brazil.

Theravance Biopharma has dosed first patient in the Phase II clinical trial of TD-0903 to treat hospitalised patients with acute lung injury (ALI) caused by Covid-19 infection. TD-0903 is believed to be able to block the cytokine storm related to ALI and prevent progression to acute respiratory distress syndrome (ARDS).

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology